_256_384.jpg)
News | February 26, 2021
Bayer delivers robust performance despite pandemic
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
ranules now has a total of 38 ANDA approvals from US FDA.
The company will be holding 26% of the share capital in each of the solar power generating companies.
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
Subscribe To Our Newsletter & Stay Updated
